

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOKE, et al

Appln. No.: 09/719,410

Filed: 12-Dec-2000

For: *GLUCAGON-LIKE PEPTIDE-1 IMPROVES
BETA-CELL RESPONSE TO GLUCOSE IN
SUBJECTS WITH IMPAIRED GLUCOSE
TOLERANCE (AMENDED)*

Art Unit: 1654

Examiner: Mohamed, A.

Atty. Docket: 0206-UTL-9

Confirm. No.: 8826

United States Patent and Trademark Office
Commissioner for Patents
Box Issue Fee
Washington, D.C. 20231

TRANSMITTAL COVER SHEET

The following documents are being submitted via EFS-Web at the United States Patent and Trademark Office on 31-Jul-2007 in response to the Notice of Allowance and Fee(s) Due, mailed May 2, 2007:

<u>Documents(s)</u>	<u>No. of Pages</u>
Part B – Fee(s) Transmittal	1
Notification of Loss of Small Entity Status	1
<i>Transmittal Cover Sheet</i>	1
Total Pages	3

Should any other fee become due or credit become payable during the pendency of these proceedings, the Commissioner is authorized to charge or credit the same to Deposit Account Number 010535.

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed via EFS-Web at the United States Patent and Trademark Office, on July 31, 2007.


Kelly B. Solomon

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOKE, et al

Appln. No.: 09/719,410

Filed: 12-Dec-2000

For: *GLUCAGON-LIKE PEPTIDE-1 IMPROVES
BETA-CELL RESPONSE TO GLUCOSE IN
SUBJECTS WITH IMPAIRED GLUCOSE
TOLERANCE (AMENDED)*

Art Unit: 1654

Examiner: Mohamed, A.

Atty. Docket: 0206-UTL-9

Confirm. No.: 8826

NOTIFICATION OF LOSS OF SMALL ENTITY STATUS

Box Issue Fee
Commissioner for Patents
Washington, D.C. 20231


Sir:

Pursuant to 37 CFR 1.27(g)(2), the undersigned hereby notifies the U.S. Patent and Trademark Office of loss of entitlement to small entity status. This notification is being submitted at the time of paying the earliest of an issue fee or a maintenance fee due after the date on which status as a small entity, as defined in 37 CFR 1.27(a), is no longer appropriate. This notification is signed by an appropriate party, as identified in 37 CFR 1.33(b).

The undersigned believes that the appropriate fee is enclosed or authorization has been given to charge the deposit account. However, in the event any additional fees are due or any amount is to be credited, the undersigned authorizes the Commissioner of Patents to debit or credit Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: 31-Jul-2007

By: 
James E. Butler
Registration No. 40,931

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936